Tumor Number and Model for End‐Stage Liver Disease Score as Selection Criteria for Resection or Embolization of Intermediate‐Stage Hepatocellular Carcinoma
Cancer Reports · 2026
DOI: 10.1002/cnr2.70697 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2026. Verfasst von Yi-Hao Yen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicin…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Hepatectomy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang Gung Memorial Hospital-Kaohsiung Medical Center.
Abstract (Originalsprache)
Background
Tumor and liver‐related factors are well‐known prognostic factors for patients with hepatocellular carcinoma (HCC). The Japanese Society of Hepatology (JSH) guidelines recommend considering liver resection (LR) for patients with multiple tumors and a tumor number ≤ 3. A previous Italian study showed that a model for end‐stage liver disease (MELD) score of > 9 indicates inadequate liver function reserve in patients with HCC undergoing LR.
Aims
We used these two parameters to predict the overall survival (OS) of patients with Barcelona clinic liver cancer (BCLC) Stage B HCC who underwent LR or transcatheter arterial chemoembolization (TACE). Methods and Results We consecutively enrolled patients with BCLC stage B HCC and Child–Pugh Class A liver disease underwent LR or TACE. Of these patients, 163 underwent LR and 270 underwent TACE. We used two parameters, that is, ≤ 3 nodules and a MELD score of ≤ 9, to subclassify BCLC stage B HCC patients. BCLC B1 had to occur concomitantly with two parameters, whereas for BCLC B2, meeting only one criterion was sufficient. The five‐year OS of BCLC B1 patients undergoing LR was 60% and those undergoing TACE was 37% ( p = 0.007). The 5‐year OS of BCLC B2 patients undergoing LR was 23% and those undergoing TACE was 18% ( p = 0.223).
Conclusion
We recommend considering LR for BCLC B1 patients, whereas TACE could be considered for BCLC B2 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Department of Surgery, Liver Transplantation Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Biostatistics Center of Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
ORCID-Profile: Yi-Hao Yen, Yueh-Wei Liu
Förderung
- Chang Gung Memorial Hospital-Kaohsiung Medical Center
Zitieren
APA
Yen, Y. H., Yong, C. C., Liu, Y. W., Li, W. F., Wang, C. C., & Lin, C. Y. (2026). Tumor Number and Model for End‐Stage Liver Disease Score as Selection Criteria for Resection or Embolization of Intermediate‐Stage Hepatocellular Carcinoma. Cancer Reports. https://doi.org/10.1002/cnr2.70697
Vancouver
Yen YH, Yong CC, Liu YW, Li WF, Wang CC, Lin CY. Tumor Number and Model for End‐Stage Liver Disease Score as Selection Criteria for Resection or Embolization of Intermediate‐Stage Hepatocellular Carcinoma. Cancer Reports. 2026. doi:10.1002/cnr2.70697
BibTeX
@article{Yen2026,
author = {Yen, Yi-Hao and Yong, Chee-Chien and Liu, Yueh-Wei and Li, Wei-Feng and Wang, Chih-Chi and Lin, Chih-Yun},
title = {Tumor Number and Model for End‐Stage Liver Disease Score as Selection Criteria for Resection or Embolization of Intermediate‐Stage Hepatocellular Carcinoma},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70697}
}
EUVIMED